Moderna (CH:0QF)
NASDAQ:0QF
0QF Stock Chart & Stats
CHF42.16
--
Market closed
CHF42.16
--
Day’s Range― - ―
52-Week RangeCHF29.35 - CHF52.01
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
CHF20.48B
Enterprise ValueCHF23.91B
Total Cash (Recent Filing)CHF5.21B
Total Debt (Recent Filing)CHF1.30B
Price to Earnings (P/E)―
Beta-0.04
Next Earnings
Jul 30, 2026EPS Estimate
-1.62Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.15
Shares OutstandingN/A
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)1.33
Price to Sales (P/S)5.90
P/FCF Ratio-5.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF35.81Price Target Upside-15.05% Downside
Rating ConsensusHold
Number of Analyst Covering16
EPS Forecast (FY)-6.76
Revenue Forecast (FY)CHF1.63B
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthModerna's sizable cash position and low leverage provide a durable liquidity buffer to fund R&D, manufacturing scale-up and near-term settlements. This balance sheet strength supports execution of multi-year clinical programs and commercialization even while revenue ramps.
Expanding Approved PortfolioRegulatory approvals (including the first flu+COVID combo in the EU) and four approved infectious-disease products materially diversify Moderna's commercial footprint. A broader approved portfolio supports recurring sales, international market access and reduced reliance on a single product.
Demonstrated Cost DisciplineManagement's execution on cost reduction (26% YoY adjusted cash cost decline, plus lower R&D and SG&A) improves cash efficiency and extends runway. Sustained cost discipline increases the firm's flexibility to invest selectively in high‑value programs while managing burn.
Bears Say
Sustained Negative Cash FlowPersistent negative OCF and FCF indicate structural cash burn tied to current revenue and expense profile. Even with cost cuts, projected drawdown to $4.5–$5.0B by year-end 2026 tightens runway and raises funding and prioritization risk if new product revenue lags expectations.
Material Litigation ExposureA large settlement already hit cost of sales and a potential additional $1.3B contingent liability creates multi-year legal and cashflow uncertainty. Ongoing appeals and trial timing could divert capital, increase cost of sales, and complicate financial planning through 2027–2028.
Negative Margins And ProfitabilityDespite revenue improvement, negative gross margin and large operating/net losses show the cost base still exceeds current commercial scale. Continued equity erosion and negative returns underscore a structural profitability gap until new products generate sustained, high-margin revenue.
Moderna News
0QF FAQ
What was Moderna’s price range in the past 12 months?
Moderna lowest stock price was CHF29.35 and its highest was CHF52.01 in the past 12 months.
What is Moderna’s market cap?
Moderna’s market cap is CHF20.48B.
When is Moderna’s upcoming earnings report date?
Moderna’s upcoming earnings report date is Jul 30, 2026 which is in 40 days.
How were Moderna’s earnings last quarter?
Moderna released its earnings results on May 01, 2026. The company reported -CHF2.676 earnings per share for the quarter, beating the consensus estimate of -CHF3.499 by CHF0.823.
Is Moderna overvalued?
According to Wall Street analysts Moderna’s price is currently Overvalued.
Does Moderna pay dividends?
Moderna does not currently pay dividends.
What is Moderna’s EPS estimate?
Moderna’s EPS estimate is -1.62.
How many shares outstanding does Moderna have?
Currently, no data Available
What happened to Moderna’s price movement after its last earnings report?
Moderna reported an EPS of -CHF2.676 in its last earnings report, beating expectations of -CHF3.499. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Moderna?
Currently, no hedge funds are holding shares in CH:0QF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Moderna Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
CHF35.81 (-15.05% Downside)
CHF35.81 (-15.05% Downside)
Blogger Sentiment
Bullish
CH:0QF Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth CHF343.8K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 86%
Bearish news 14%
Bearish news 14%
Technicals
SMA
Positive
20 days / 200 days
Momentum
151.81%
12-Months-Change
Fundamentals
Return on Equity
-36.73%
Trailing 12-Months
Asset Growth
-9.57%
Trailing 12-Months
Company Description
Moderna
Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and respiratory syncytial virus (RSV); latent viral infections such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), and varicella-zoster virus (VZV); and public health threats like Zika and Nipah. Additionally, Moderna is advancing systemic secreted and cell surface-targeted therapeutics, an array of cancer vaccines (including personalized, KRAS, and checkpoint varieties), intratumoral immuno-oncology products, localized regenerative treatments, systemic intracellular medicines, and inhaled pulmonary solutions. Moderna maintains strategic alliances with several prominent entities, including AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics, Inc., Metagenomi, Inc., the Defense Advanced Research Projects Agency (DARPA), the Biomedical Advanced Research and Development Authority (BARDA), the Institute for Life Changing Medicines, and The Bill & Melinda Gates Foundation. It also holds a collaboration and license agreement with Chiesi Farmaceutici S.P.A. Founded in 2010 as Moderna Therapeutics, Inc., the company officially became Moderna, Inc. in August 2018. Its corporate headquarters are located in Cambridge, Massachusetts.
0QF Company Deck
0QF Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a predominantly constructive commercial and scientific update: strong Q1 revenue growth (driven by international strategic partnerships), multiple regulatory approvals (including the first flu+COVID combo), meaningful cost reductions (adjusted cash cost down 26% YoY) and continued pipeline advancement across respiratory, oncology and rare diseases. Offsetting these positives were a large, near-term litigation settlement charge recognized in Q1 that materially increased cost of sales and GAAP loss, potential contingent legal exposure (up to $1.3B) with multi‑year timing uncertainty, and expected cash drawdown through 2026. On balance, the company demonstrated operational execution and long‑term value drivers while managing a significant one‑time legal headwind.View all CH:0QF earnings summaries0QF Revenue Breakdown
61.68% U.S.
2.73% Europe
35.60% Rest of World
0QF Stock 12 Month Forecast
Average Price Target
CHF35.81
▼(-15.05% Downside)
Technical Analysis
Ionis Pharmaceuticals
―
Protagonist Therapeutics
―
Rhythm Pharmaceuticals
―
Revolution Medicines
―
―
Options Prices
Currently, No data available
---